药明生物（2269.HK）深度解析：业绩超预期背后的增长密码

<h4 data-pm-slice="0 0 []"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">一、核心业绩速览：营收利润双增长，毛利率显著提升</span></span></h4><p><span leaf=""><br /></span><span leaf="">2025年上半年，药明生物交出了一份亮眼的成绩单：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">营收</span></strong><section><span leaf="">：99.5亿元（同比增长16.1%），剔除XDC业务后增长9%</span><p><span x-noteelement="excluded" aria-describedby=":r4g:"></span></p></section></li><li><strong><span leaf="">净利润</span></strong><section><span leaf="">：23.4亿元（同比大增56%），非国际财务报告准则净利润增长12%</span></section></li><li><strong><span leaf="">毛利率</span></strong><section><span leaf="">：42.7%（同比提升3.6个百分点）</span></section></li><li><strong><span leaf="">3年服务订单</span></strong><section><span leaf="">：42.1亿美元（较2024年底增长15.3%）</span></section></li></ul><p><span leaf=""><br /></span><em><span leaf="">（图示：毛利率提升驱动利润增速显著高于营收增速）</span></em></p><p><strong><span leaf="">关键亮点</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><section><span leaf="">新增项目86个（含9个"赢分子"战略项目），超过去年同期水平</span><p><span x-noteelement="excluded" aria-describedby=":r4i:"></span></p></section></li><li><section><span leaf="">双抗/多抗项目增长36.6%至168个，ADC项目增长34.7%至225个</span><p><span x-noteelement="excluded" aria-describedby=":r4k:"></span></p></section></li><li><section><span leaf="">日本、韩国等新兴市场收入翻倍增长（+136.1%）</span><p><span x-noteelement="excluded" aria-describedby=":r4m:"></span></p></section></li></ul><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">二、业务亮点：双抗/ADC引领增长，"赢分子"战略显成效</span></span><span leaf=""><br /></span><strong><span leaf=""><br /></span></strong></h4><h4><strong><span leaf="">三大业务支柱表现</span></strong><span leaf="">：</span></h4><ol class="list-paddingleft-1"><li><strong><span leaf="">早期项目（D段）</span></strong><section><span leaf="">：新增86个项目，其中9个来自"赢分子"战略</span><p><span x-noteelement="excluded" aria-describedby=":r4o:"></span></p></section></li><li><strong><span leaf="">后期项目（M段）</span></strong><section><span leaf="">：25个项目进入PPQ阶段（2025年计划）</span></section></li><li><strong><span leaf="">商业化项目</span></strong><section><span leaf="">：已有21个商业化项目在运行</span></section></li></ol><p><strong><span leaf="">技术平台优势</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">双抗/多抗平台</span></strong><section><span leaf="">：CD3 TCEs技术平台具备低毒性特征</span><p><span x-noteelement="excluded" aria-describedby=":r4q:"></span></p></section></li><li><strong><span leaf="">ADC平台</span></strong><section><span leaf="">：全球领先的抗体偶联技术</span></section></li><li><strong><span leaf="">细胞株平台</span></strong><section><span leaf="">：已应用于600多个项目，可产生0.5%的销售分成</span><p><span x-noteelement="excluded" aria-describedby=":r4s:"></span></p></section></li></ul><p><span leaf=""><br /></span><em><span leaf="">（双抗和ADC项目占比已达71%，成为增长主力）</span></em></p><p><span x-noteelement="excluded" aria-describedby=":r4u:"></span></p><p><span leaf=""><br /></span></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">三、财务健康度：现金流改善，研发投入持续</span></span></h4><p><span leaf=""><br /></span><strong><span leaf="">财务指标亮点</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">经营现金流</span></strong><section><span leaf="">：上半年-0.9亿元（季节性因素），全年有望转正</span></section></li><li><strong><span leaf="">资本开支</span></strong><section><span leaf="">：2025年预计53亿元（原计划60亿元），主要用于新加坡和美国产能扩张</span><p><span x-noteelement="excluded" aria-describedby=":r50:"></span></p></section></li><li><strong><span leaf="">净现金状态</span></strong><section><span leaf="">：现金及等价物82.8亿元，财务结构稳健</span></section></li></ul><p><strong><span leaf="">研发投入</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><section><span leaf="">上半年研发费用8.6亿元，占营收8.6%</span></section></li><li><section><span leaf="">重点投向CD3 TCEs等创新技术平台</span></section></li></ul><p><span leaf=""><br /></span><em><span leaf="">（爱尔兰、新加坡、美国基地陆续投产提升全球交付能力）</span></em></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">四、未来增长点：IP收入或成新引擎</span></span></h4><p><span leaf=""><br /></span><strong><span leaf="">知识产权收入三大来源</span></strong><span leaf="">：</span></p><ol class="list-paddingleft-1"><li><strong><span leaf="">销售分成</span></strong><section><span leaf="">：商业化阶段项目销售提成（部分项目可达个位数百分比）</span></section></li><li><strong><span leaf="">细胞株授权</span></strong><section><span leaf="">：现有600多个项目可产生持续现金流</span></section></li><li><strong><span leaf="">里程碑付款</span></strong><section><span leaf="">：CD3 TCE项目潜在收入可达2亿美元</span><p><span x-noteelement="excluded" aria-describedby=":r52:"></span></p></section></li></ol><p><strong><span leaf="">管理层预期</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><section><span leaf="">IP收入未来5-6年有望贡献30%利润</span><p><span x-noteelement="excluded" aria-describedby=":r54:"></span></p></section></li><li><section><span leaf="">2025年全年营收指引上调至14-16%增长（原12-15%）</span><p><span x-noteelement="excluded" aria-describedby=":r56:"></span></p></section></li></ul><p><span leaf=""><br /></span><em><span leaf="">（知识产权收入将成为新的利润增长点）</span></em></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf="">五、机构观点：高盛维持"中性"评级</span></h4><p><span leaf="">（插入估值对比表）</span><span leaf=""><br /></span><strong><span leaf="">高盛最新判断</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><strong><span leaf="">目标价</span></strong><section><span leaf="">：29.3港元（较现价30.62港元有4.3%下行空间）</span><p><span x-noteelement="excluded" aria-describedby=":r58:"></span></p></section></li><li><strong><span leaf="">估值逻辑</span></strong><section><span leaf="">：2026年23倍PE（当前25.7倍2025年PE）</span></section></li><li><strong><span leaf="">关键担忧</span></strong><section><span leaf="">：</span></section></li><ul class="list-paddingleft-1"><li><section><span leaf="">美国《生物安全法案》潜在影响</span></section></li><li><section><span leaf="">全球生物科技融资环境波动</span></section></li></ul></ul><p><strong><span leaf="">同业估值对比</span></strong><span leaf="">：</span></p><table><thead><tr><th><section><span leaf="">指标</span></section></th><th><section><span leaf="">药明生物</span></section></th><th><section><span leaf="">行业平均</span></section></th></tr></thead><tbody><tr><td><section><span leaf="">2025年PE</span></section></td><td><section><span leaf="">25.7x</span></section></td><td><section><span leaf="">20-25x</span></section></td></tr><tr><td><section><span leaf="">PEG</span></section></td><td><section><span leaf="">1.8</span></section></td><td><section><span leaf="">1.5-2.0</span></section></td></tr><tr><td><section><span leaf="">市销率</span></section></td><td><section><span leaf="">6.2x</span></section></td><td><section><span leaf="">5-7x</span></section></td></tr></tbody></table><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><h4><span leaf=""><br /></span></h4><h4><span leaf=""><br /></span></h4><h4><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">六、投资看点：短期催化剂与长期价值</span></span><span leaf=""><br /></span><strong><span leaf=""><br /></span></strong></h4><h4><strong><span leaf="">短期催化剂</span></strong><span leaf="">：</span></h4><ol class="list-paddingleft-1"><li><section><span leaf="">9月美国《生物安全法案》最终版本落地</span></section></li><li><section><span leaf="">下半年IP收入确认进度</span></section></li><li><section><span leaf="">新加坡基地产能释放情况</span></section></li></ol><p><strong><span leaf="">长期价值</span></strong><span leaf="">：</span></p><ul class="list-paddingleft-1"><li><section><span leaf="">全球化产能布局（中国、爱尔兰、新加坡、美国）</span></section></li><li><section><span leaf="">技术平台持续领先（双抗、ADC、CD3 TCEs）</span><p><span x-noteelement="excluded" aria-describedby=":r5a:"></span></p></section></li><li><section><span leaf="">IP收入占比提升改善盈利结构</span></section></li></ul><p><span leaf=""><br /></span><em><span leaf="">（30港元为关键心理关口，28港元有强支撑）</span></em></p><hr style="border-style: solid;border-width: 1px 0 0;border-color: rgba(0,0,0,0.1);-webkit-transform-origin: 0 0;-webkit-transform: scale(1, 0.5);transform-origin: 0 0;transform: scale(1, 0.5);" /><blockquote><p><strong><span leaf="">小编观察</span></strong><span leaf="">：药明生物正从"服务提供商"向"技术平台公司"转型，知识产权收入将成为估值重塑的关键。投资者可重点关注：</span><span leaf=""><br /></span><span leaf="">① 每季度新增项目数量与结构</span><span leaf=""><br /></span><span leaf="">② IP收入确认进度</span><span leaf=""><br /></span><span leaf="">③ 全球生产基地利用率提升情况</span></p></blockquote><section><span leaf=""><br /></span></section><p style="display: none;"><mp-style-type data-value="3"></mp-style-type></p>